Immune Pharmaceuticals Files New Patent Application for Ceplene in Combination with Checkpoint Inhibitors

NEW YORK, Feb. 10, 2016 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ: IMNP), “Immune”, a clinical-stage biopharmaceutical company, announced today that it has filed a patent application directed to the treatment of Acute Myeloid Leukemia and other cancers. The new invention provides methods of treating cancer by administration of Ceplene (histamine dihydrochloride) in combination with immune checkpoint…